Regenxbio (RGNX) Tops Q3 EPS by 10c

Regenxbio (NASDAQ: RGNX) reported Q3 EPS of ($1.20), $0.10 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $29.7 million versus the consensus estimate of $24.63 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Key things to know ahead of SK Hynix’s blockbuster US listing
• Leidos and Rune Technologies partner on AI military logistics
• 30-year mortgage rate edges up to 6.49%, Freddie Mac says